生命科学资讯
生物技术与制药领域的最新动态
Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News
Ngs 肿瘤学市场即将迎来繁荣 | Illumina • Roche • Thermo Fisher Scientific - openPR.com
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com
罗氏集团员工数量:2007年至2025年 - Statista
Number of Roche Group employees from 2007 to 2025 - Statista
礼来再次押注中国市场;罗氏展示多发性硬化症数据
Lilly bets again on China drugs; Roche showcases MS data
#ACTRIMS26:罗氏多发性硬化症药物芬布替尼优于奥瑞珠单抗,降低残疾进展风险12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
罗氏芬尼布替尼在多发性硬化症治疗中展现十年首次突破——欧洲药品评论
Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review
罗氏公布BTK抑制剂在Ocrevus试验中三期多发性硬化症成功的数据——Fierce Biotech
Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech
新披露显示,罗氏基因泰克去年裁员至少489人。
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
新文件披露:基因泰克去年裁员至少489人——来自《激烈生物科技》
Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech
罗氏重返RNA领域,以17亿美元收购赛诺基因项目。
Roche's return to RNA continues with $1.7B deal for Sanegene program
罗氏以17亿美元收购赛诺基因药物,继续RNA领域回归之路——Fierce Biotech
Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech
罗氏扩大墨西哥临床研究规模,投资12亿比索——墨西哥商业新闻
Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News
罗氏2025年利润因美元走软而受挫——医疗器械网络
Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network
罗氏2025年利润因美元走软而受挫——医药科技
Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology
罗氏诊断业务在2025年微增2%,中国市场逆风冲击亚太区销售。
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
罗氏GLP-1药物在晚期肥胖试验中展现出“强劲”减重效果——欧洲药品评论
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
罗氏季度清理计划中剔除Kiniksa纤维化药物,放弃二期研发投入1亿美元——Fierce Biotech报道
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
罗氏公布GLP-1/GIP双重受体激动剂二期研究积极结果 | 医药行业高管
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
罗氏在肥胖症领域落后,展示GLP-1注射剂新数据
Roche, trailing in obesity, showcases new data for GLP-1 shot